Business Wire

MINDRAY

5.12.2022 05:01:39 CET | Business Wire | Press release

Share
Mindray Introduces New Wearable Patient Monitoring System, Refining Clinician’s Workflow to Track Patient Conditions

Mindray (SZSE: 300760), a global leader in providing advanced medical device solutions, today launches the mWear™ system, an all-new wearable patient monitoring solution that enables an efficient workflow to continually monitor patient conditions and deliver patient-centric care.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221204005001/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Nurse and Patient with mWear (Photo: Business Wire)

With the increased shortages of beds and staff in today’s hospitals, postoperative complications and late patient deterioration detection in general wards have become more challenging and in turn require immediate action. This is where Mindray’s mWear™ system comes into play. The system refines routine patient monitoring by combining all the benefits of complete wireless interconnection with accurate multi-parameter monitoring, streamlined workflows and seamless integration for home-hospital settings, helping to improve clinical outcomes throughout the patient journey.

mWear™ supports comprehensive and precise measurements of vital signs including ECG, oxygen saturation, noninvasive blood pressure, respiration rate, pulse rate, and temperature. It features excellent anti-interference ability with patented Anti-motion Algorithm, allowing patients to move without restrictions and minimizing false alarms for clinicians to identify true abnormalities. Leveraging specialized health parameters, status indicators and time analysis to capture patients' physical activities and sleep, mWear™ provides a comprehensive set of patient-related data to assist caregivers in evaluating patient’s recovery status completely and objectively.

The system enables customizable measurement settings and monitoring modes to fit different clinical demands for a smoother workflow and higher efficiency. With the highlights of vital sign changes, auto-triggered emergency mode and alarm escalations, clinicians can effectively identify early signs of deterioration and offer timely interventions.

Apart from in-hospital monitoring, this wearable solution also allows hospitals to extend their care service seamlessly to patients’ home through the Home-hospital App. Its ability to provide continuous medical-grade monitoring for patients staying at home after discharge has revolutionized the whole patient care process with enhanced safety and flexibility.

To facilitate consistent and systemic monitoring of all patients inside and outside the hospital, mWear™ deploys a universal CMS platform so that all patient-related clinical data throughout the healthcare journey can be displayed, analyzed, alarmed and reported for a more comprehensive picture of patient health. It also allows hospitals to leverage the existing Mindray IT architecture to reduce installation and maintenance costs.

“Integrating the latest monitoring technologies to address clinical needs, we believe that the mWear™ wearable monitoring system is a solid step forward to reshape the future of patients’ journey and take continuous patient monitoring to a new level,” said Ralph Zhao, General Manager of Global PMLS Sales & Marketing Department, Mindray. “It is Mindray’s unremitting commitment to continue upgrading medical solutions that bring high-quality healthcare to every point of care.”

About Mindray

Mindray is a leading developer, manufacturer, and supplier of medical device solutions and technologies used in healthcare facilities around the globe. The company empowers healthcare professionals through innovative, high-value solutions that help create the next generation of life-saving tools of patient monitoring and life support, in-vitro diagnostics, and medical imaging. For more information, please visit http://www.mindray.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221204005001/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Oral‑B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability‑Focused Oral Health Studies13.5.2026 09:06:00 CEST | Press release

Oral‑B and iADH build on four years of action to advance inclusive oral care and whole‑body health41% of Europeans identify as living with a disability, representing a four‑point increase wave‑on‑wave Oral‑B today announces The Big Rethink 2026, the next evolution of its flagship oral health inclusion programme, developed in partnership with the International Association for Disability and Oral Health (iADH). The new phase introduces Project Steady, one of Europe’s largest real‑world studies exploring oral care experiences among people with disabilities, their carers and dental professionals. The programme aims to reduce everyday barriers to oral care through inclusive design, evidence-based research and professional education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511175864/en/ Oral B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability Focused Oral Health Studies Oral health for Whole-Bo

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results13.5.2026 08:38:00 CEST | Press release

FY2025 Pipeline Successes Set the Stage for Pivotal Product LaunchesAchieved Latest FY2025 Management GuidanceTakeda is Entering a New Era & Transforming for Growth Acceleration Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER). Core Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth. Reported Operating Profit increased by 19.3% YoY at AER, also reflecting a step-down in amo

Allianz Delivers Record Operating Profit in Strong Start to 202613.5.2026 07:20:00 CEST | Press release

1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net income advances by 48.4 percent to 3.8 billion euros, impacted by the sale of the stakes in our Indian Joint Ventures. Underlying growth, which adjusts for the sale effects and offsetting measures, is strong at 7 percent2Core earnings per share grow 50.7 percent and reach 9.96 euros. Adjusted for the above-mentioned effects, underlying growth is excellent at 9 percent 2Annualized core RoE at 24.2 percent, underlying level very strong at 18 percent 2Solvency IIratio3 increases by 2 percentage points to 221 percent4. Capital generation was str

Abu Dhabi's Phoenix Group Partners with DC Max to Unlock $8 Billion European AI Data Center Opportunity, with Lyon, France as First Deployment13.5.2026 07:00:00 CEST | Press release

18MW AI-ready facility developed in partnership with DC Max, a French data center developer with a 1GW pipeline Partnership provides preferential access to DC Max’s development pipeline, accelerating Phoenix’s goal towards an excess of 1GW global AI and HPC platform across Europe and the GCC Phoenix has already acquired the land for the Lyon site, which comes with secured permits, grid connection in place and available power, enabling construction to begin in July 2026, with delivery targeted between Q4 2027 and Q1 2028 Phoenix Group PLC (ADX: PHX), an IHC portfolio company and global digital infrastructure operator, today announced a strategic partnership with DC Max to develop its first European AI data center, an 18MW facility in Lyon, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512531777/en/ From left to right: Matthias Luecker, Chairman of DC Max, and Munaf Ali, Co-Founder and Group CEO of Phoenix Group, d

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca13.5.2026 07:00:00 CEST | Press release

Agreement includes license for Owkin’s AI Scientist, K Pro, for three years. As part of this license, Owkin will develop novel biopharma agents for AstraZeneca, usable through K Pro. This will include capabilities to quickly analyze and forecast the competitive landscape for specific pharmaceutical targets, assets, and trials. Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin’s AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the end-to-end development of AI agents to run on K Pro, integrated within AstraZeneca’s IT infrastructure and decision workflows. The new agents' functionality is intended to help AstraZeneca’s decision-making

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye